Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM) (TIDM)
|ClinicalTrials.gov Identifier: NCT00529191|
Recruitment Status : Completed
First Posted : September 14, 2007
Results First Posted : March 8, 2013
Last Update Posted : March 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|Type 1 Diabetes||Drug: Atorvastatin Other: Placebo||Phase 2|
Type 1 diabetes is an autoimmune disease that is characterized by destruction of the insulin-producing beta cells of the pancreas. T1DM therapy requires insulin administration, either by multiple daily injections or by insulin pump. However, in many patients, blood sugar control remains suboptimal and complications develop that shorten life expectancy and severely impact quality of life. At the time of diagnosis, most patients still have significant residual beta cell function. Previous research has shown that weakening the immune system's attack on the pancreatic beta cells may help to preserve or potentially increase insulin production.
Preliminary studies have shown that members of the statin family of medications, including atorvastatin (Lipitor®), preserve beta cell function in a mouse model of type 1 diabetes. These finding suggest that use of atorvastatin in combination with insulin therapy may delay and potentially reverse the destruction of beta cells in patients who have recently developed type 1 diabetes. Atorvastatin (Lipitor®) is approved for use in adults and children (>10 years of age) who have elevated blood cholesterol levels. This study will examine whether atorvastatin (Lipitor®) may also help the body preserve insulin production in patients with newly diagnosed (within 8 weeks) type 1 diabetes.
Patients will be randomly assigned to take either atorvastatin (Lipitor®) or placebo. Two out of every 3 patients will receive atorvastatin and 1 out of 3 will get placebo. As this is a double-blinded study, neither the care team nor the patient will know if they are actually taking atorvastatin (Lipitor®). Patients who have given consent to participate in the study and pass the required screening tests will take the assigned treatment every day for 12 months. All patients will begin taking 10 mg once daily, the recommended starting dose. After 4 weeks, the dose will be increased to 20 mg. In addition to a high standard of diabetes care and the medication, patients will have blood tests during 7 visits over an 18 month period.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Phase II, Double Blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin in Subjects With Newly Diagnosed Type 1 Diabetes Mellitus.|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||July 2011|
|Actual Study Completion Date :||July 2013|
Two out of every three patients will receive atorvastatin.
Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
Other Name: Lipitor
Placebo Comparator: Placebo
One out of three subjects will receive a placebo.
One out of three subjects will receive a placebo.
- Efficacy of a Daily Dose of Atorvastatin to Maintain Islet Cell Function as Measured by a 4-hour C-peptide Area Under Curve (AUC) in Patients With Newly Diagnosed Type 1 Diabetes Mellitus [ Time Frame: Baseline vs 12-month ]The change in C-peptide measurements collected over a 4 hour period (0, 30, 60, 90, 120, 150, 180, 210 and 240 minutes) after a Mixed Meal Tolerance Test at baseline vs 12 months post-treatment were calculated. The area under the curve for these combined measurements is calculated and the unit of measure is nanogram x minutes / mL. Efficacy (success) is defined by < 7.5% reduction in AUC for 4-hr MMTT.
- % Subjects Without Change in 2-hour C-peptide AUC in Response to the MMTT at Baseline vs. 12 Months [ Time Frame: Baseline vs 12 months ]The C-peptide AUC measurements are collected over a 2 hour period (with 30 minute intervals) after a Mixed Meal Tolerance Test. The area under the curve from these combined measurements (from 0 to 120 or 0 to 240 minutes) is calculated and the unit of measure is nanogram*minutes/ml. The change in C-peptide AUC in response to a 2 hour MMTT at baseline vs 12 months were calculated, and efficacy (success) is defined as < 7.5% reduction.
- Mean Daily Insulin Dose Per kg Body Weight for 7 Days [ Time Frame: Visit 1, 2, 3, 4, 5, 6, 7 ]Mean daily insulin dose per kg body weight for the 1 week preceding each scheduled study visit.
- Levels of HbA1c at Months 3, 6, 9, 12 and 18 [ Time Frame: 3, 6, 9, 12, and 18 months ]
- Blood Glucose Control (Number of Participants With Hypoglycemia) [ Time Frame: Baseline, Month 12, Month 18 ]Blood glucose control as determined from home glucose meter downloads for the 1 week preceding the visit. The number of subjects with hypoglycemic episodes requiring treatment (BG < 70 mg/dl)
- Number of Episodes of Hypoglycemia Requiring Any Treatment [ Time Frame: Baseline, Month 12, Month 18 ]number of episodes of hypoglycemia requiring any treatment, defined by the need for treatment with glucagon or third party intervention.
- Study Drug Compliance Rate Overall [ Time Frame: 12 months treatment ]Compliance is defined as >=80% expected dosage consumed during the visit period.
- HDL and LDL Cholesterol Levels in Participants Stratified by the Preservation of Islet Cell Function [ Time Frame: Baseline, Week 1, Month 3, Month 6, Month 9, Month 12, ]
Relationship between atorvastatin's effect on HDL and LDL cholesterol and the preservation of islet cell function.
Islet cell preservation defined as: <7.5% Reduction in C-Pep
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00529191
|United States, Pennsylvania|
|Diabetes Center for Children & Clinical Translational Research Center|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||Steven M Willi, M.D||Children's Hospital of Philadelphia|